Novo Nordisk to Acquire Akero Therapeutics for $5.2B
- SSCTR Exco
- Oct 12
- 1 min read
Published on LinkedIn (via Spencer Knight)
Novo Nordisk has announced its plan to acquire Akero Therapeutics for up to $5.2 billion, expanding beyond diabetes and obesity into metabolic liver disease. The deal adds Akero’s efruxifermin, a promising therapy for metabolic-associated steatohepatitis (MASH), one of the most prevalent obesity-related conditions worldwide.
👉 Read the full post: Big News in Liver Disease: Novo to Acquire Akero for $5.2B
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments